Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Authors / Laura Holtmann, Stephen Klutz, Martin Lobedann and Dr. Schembecker

Laura Holtmann, Stephen Klutz, Martin Lobedann and Dr. Schembecker

Laura Holtmann started studying biochemical engineering at the TU Dortmund University in 2009 and completed her bachelor’s degree in 2013 and her master’s degree in 2014. She wrote her master thesis at INVITE GmbH in Leverkusen under the topic “Cost evaluation of monoclonal antibody production processes in different operation modes”. Since 2015, she works as a research associate at INVITE GmbH where she focuses on viral clearance for continuous, biopharmaceutical processes. Stephan Klutz completed his diploma degree in mechanical engineering at RWTH Aachen University in 2011. From 2011 to 2015 he worked as a research associate at INVITE GmbH where he focused on continuous processing of monoclonal antibodies. In parallel he completed his master´s degree in economics at RWTH Aachen University in 2015. Since 2016, he works in the field of project management at Bayer. Martin Lobedann is a biochemical engineer and a PhD in Biotech-Engineering. He joint Bayer in 2010 before having an assignment at the Bayer daughter company Invite GmbH in 2011, heading the group Biotechnology. He is working in the field of biopharma covering conceptual design, engineering, process control and process analytical technology. Dr. Schembecker received his diploma as well as his Ph.D. in Chemical Engineering from TU Dortmund University in Germany. He is co-founder of the consultancy firms Process Design Center, inosim Consulting and b-value. In September 2005 he was appointed Professor for Plant and Process Design at the Department of Biochemical and Chemical Engineering of TU Dortmund University. His research interests focus on the conceptual design and simulation of (bio)chemical processes with special interest in innovative downstream processes and on module based plant design.

  • Contributions

mAbs: Hybrid Style

September 21, 2016

Batch or continuous processing? That is the question. With monoclonal antibodies, there are benefits in combining the best of both worlds.

1 min read

mAbs: Hybrid Style

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.